(Q35871889)

English

Fosamprenavir: advancing HIV protease inhibitor treatment options

scientific article published in September 2004

In more languages

default for all languages

No label defined

No description defined

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

10 August 2017

1 reference

Europe PubMed Central

title

Fosamprenavir: advancing HIV protease inhibitor treatment options (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

10 August 2017

Stephen Becker

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

Lorna Thornton

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

language of work or name

English

0 references

publication date

1 September 2004

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

published in

Expert Opinion on Pharmacotherapy

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

volume

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

issue

9

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

page(s)

1995-2005

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

cites work

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.9.1995

retrieved

21 January 2018

Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.9.1995

retrieved

21 January 2018

SOLO: 48-week efficacy and safety comparison of once-daily fosamprenavir /ritonavir versus twice-daily nelfinavir in naive HIV-1-infected patients

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1517%2F14656566.5.9.1995

retrieved

21 January 2018

Identifiers

DOI

10.1517/14656566.5.9.1995

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

PubMed publication ID

15330736

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15330736

retrieved

10 August 2017

(Q35871889)

Fosamprenavir: advancing HIV protease inhibitor treatment options

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)